NURS FPX 4055 Assessment 4 Health Promotion Plan Presentation
NURS FPX 4055 Assessment 4 Health Promotion Plan Presentation
Name
Capella university
NURS-FPX4055 Optimizing Population Health through Community Practice
Prof. Name
Date
Health Promotion Plan Presentation
Good morning, everyone. We are glad partners have joined today’s session. This session focuses on preventing Human Papillomavirus (HPV) infection in adolescents and young adults aged 11 to 26 in Schwenksville, Pennsylvania. The presentation will provide information on HPV, its association with cancer, the benefits of timely immunization, and strategies for discussing HPV vaccination with healthcare providers and family members. Our approach is based on the SMART goals we set and the Healthy People 2030 objectives. Let’s begin with an overview of today’s presentation.
Presentation Roadmap
Throughout the presentation, we will:
- Share key facts about HPV, its transmission, and its link to cancer.
- Discuss the importance, safety, and effectiveness of the HPV vaccine.
- Encourage participants to commit to scheduling the HPV vaccination within 30 days.
- Build participants’ confidence in discussing HPV vaccination with healthcare providers and family members.
- Engage participants through interactive activities and discussions.
- Evaluate participant knowledge and confidence through a post-session quiz and survey.
Key Information About HPV and Its Link to Cancer
Human Papillomavirus (HPV) is a common virus that spreads through skin-to-skin contact, mainly during sexual activity. In Pennsylvania, only 68.7% of adolescents are fully vaccinated against HPV-related cancers, with rural areas like Schwenksville showing even lower vaccination rates (48.7%). Schwenksville has high HPV-associated cancer incidence and mortality rates, highlighting the urgent need for vaccine awareness and implementation (PA.gov, 2025).
HPV is responsible for several types of cancer, including cervical, anal, throat, and genital cancers. High-risk strains like HPV 16 and 18 can lead to abnormal cell changes that result in cancer (Huber et al., 2021). While most HPV infections clear up on their own, persistent infections can lead to serious health problems. Early detection is key, as HPV infections can remain asymptomatic for years. Vaccination offers the best protection against high-risk HPV infections, significantly reducing the likelihood of developing HPV-related cancers. In addition to vaccination, regular screenings are crucial in fighting the cancer burden caused by HPV.
Benefits of Timely HPV Vaccination
HPV vaccination is a crucial tool for preventing certain cancers and genital warts. Vaccinating at a young age (around 11 or 12 years) before exposure to the virus offers the most benefits. Early vaccination optimizes the immune response and provides long-lasting protection against HPV-related diseases (Hoes et al., 2021). When administered before exposure to the virus, the vaccine is highly effective in preventing future HPV-related health issues and reduces the risk of developing HPV-related cancers.
Cervical cancer, the second most common cancer in women globally, is primarily caused by HPV. Timely vaccination helps reduce the risk of cervical cancer by preventing high-risk strains of HPV (Huber et al., 2021). Vaccinating girls at an early age significantly lowers cervical cancer incidences, improving long-term health outcomes for women worldwide.
HPV vaccination also reduces the risk of other HPV-related cancers, including anal, penile, and oropharyngeal cancers (Cheng et al., 2020). Vaccinating adolescents helps reduce the future burden of these cancers, leading to healthier individuals and communities.
Moreover, the HPV vaccine helps prevent genital warts, which can be painful and cause emotional distress. Vaccination not only reduces the incidence of genital warts but also alleviates the social stigma and psychological effects associated with the condition. Timely vaccination also plays a critical role in reducing the spread of HPV. By vaccinating adolescents early, we lower the overall prevalence of HPV within the community, contributing to herd immunity against HPV-related diseases (Xu et al., 2024).
Strategies for Discussing HPV Vaccination
Effective communication is essential when discussing HPV vaccination with healthcare providers and family members. Here are three strategies to facilitate these discussions:
- Using Evidence-Based Facts: Provide reliable information from trusted sources such as the CDC or WHO. Sharing statistics about the vaccine’s effectiveness in preventing cancer and its safety can help lay a strong foundation for the conversation and counter any misinformation.
-
Asking Informed Questions: Encourage open dialogue by asking thoughtful questions such as, “What are the long-term benefits of the HPV vaccine?” or “How does the vaccine impact my health?” These questions promote discussion and address concerns (Kassymbekova et al., 2023).
-
Addressing Common Myths: Many myths surround the HPV vaccine, such as the misconception that it encourages early sexual activity. Providers can clarify that the vaccine’s purpose is to prevent cancer and other HPV-related diseases, not to influence sexual behavior.
Developed SMART Goals with the Participants
We set several SMART goals to guide this session and measure its success. These goals are as follows:
- Goal 1: By the end of the session, 90% of participants should correctly identify at least three key facts about HPV and its connection to cancer.
- Goal 2: At least 80% of participants should commit to scheduling their first dose of the HPV vaccine within the next 30 days.
- Goal 3: 85% of participants should leave feeling more confident in discussing HPV vaccination with healthcare providers and family members.
These goals aim to empower participants with the knowledge to advocate for their health and community.
Session Evaluation on Developed SMART Goals
The session was successful in achieving many of our SMART goals. A total of 92.5% of participants correctly identified three or more key facts about HPV, meeting our first goal. However, for the second goal, only 75% of participants verbally committed to scheduling the vaccine within 30 days, falling short of the 80% target. Finally, 85% of participants reported feeling more confident discussing HPV vaccination, reaching our third goal.
Some challenges were noted. Several participants, particularly teenagers, were hesitant to make immediate vaccination commitments and preferred to discuss the decision with their families. Additionally, while confidence in discussing the vaccine increased, four participants expressed discomfort with handling common myths about the vaccine. These observations suggest that future sessions could benefit from more family engagement and structured myth-busting activities.
Session Evaluation on Healthy People 2030 Objectives
The session supported the goals of Healthy People 2030 by increasing awareness of HPV vaccination and promoting early vaccination to reduce HPV infections and related cancers (U.S. Department of Health and Human Services, n.d.). The session contributed to the empowerment of communities to make informed health decisions, as evidenced by the 92.5% knowledge gain and 85% increase in confidence to discuss vaccination.
However, the vaccine initiation rate fell short of the target. To align future sessions with Healthy People 2030 objectives, it is essential to incorporate more opportunities for family engagement, discussions about vaccine safety, and follow-up communication. These changes will likely increase vaccination uptake and help meet national health promotion goals.
Conclusion
In conclusion, this session reinforced the importance of HPV vaccination in preventing cancer and improving long-term health in adolescents and young adults in Schwenksville, PA. While there were significant knowledge gains, areas for improvement remain, particularly in encouraging timely vaccination and addressing misconceptions. By making adjustments for future sessions, we can better meet the Healthy People 2030 objectives and further empower our community to take charge of their health.
References
Cheng, L., Wang, Y., & Du, J. (2020). Human papillomavirus vaccines: An updated review. Vaccines, 8(3), 391. https://doi.org/10.3390/vaccines8030391
Hoes, J., Pasmans, H., Schurink-van ’t Klooster, T. M., van der Klis, F. R. M., Donken, R., Berkhof, J., & de Melker, H. E. (2021). Review of long-term immunogenicity following HPV vaccination: Gaps in current knowledge. Human Vaccines & Immunotherapeutics, 18(1). https://doi.org/10.1080/21645515.2021.1908059
NURS FPX 4055 Assessment 4 Health Promotion Plan Presentation
Huber, J., Mueller, A., Sailer, M., & Regidor, P.-A. (2021). Human papillomavirus persistence or clearance after infection in reproductive age. What is the status? Review of the literature and new data of a vaginal gel containing silicate dioxide, citric acid, and selenite. Women’s Health, 17, 174550652110207. https://doi.org/10.1177/17455065211020702
Kassymbekova, F., Zhetpisbayeva, I., Tcoy, E., Dyussenov, R., Davletov, K., Rommel, A., & Glushkova, N. (2023). Exploring HPV vaccine knowledge, attitudes, barriers and information sources among parents, health professionals and teachers in Kazakhstan: A mixed-methods study protocol. BMJ Open, 13(9), e074097. https://doi.org/10.1136/bmjopen-2023-074097
PA.gov. (2025). Dear VFC provider. https://www.pa.gov/content/dam/copapwp-pagov/en/health/documents/topics/documents/programs/immunizations/3.3.25%20-%202025%20HPV%20Call-to-Action%20Letter%20and%20Resources.pdf
U.S. Department of Health and Human Services. (n.d.). Vaccination – Healthy People 2030. Health.gov. https://odphp.health.gov/healthypeople/objectives-and-data/browse-objectives/vaccination
NURS FPX 4055 Assessment 4 Health Promotion Plan Presentation
Xu, M., Choi, J., Capasso, A., & DiClemente, R. (2024). Improving HPV vaccination uptake among adolescents in low-resource settings: Sociocultural and socioeconomic barriers and facilitators. Adolescent Health Medicine and Therapeutics, 15, 73–82. https://doi.org/10.2147/ahmt.s394119